Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica
Greiner, J.; Miehe, M.; Weber, H.; Stoimenov, A.; Sönnichsen, N.; Diezel, W.
Dermatologische Monatschrift 176(2-3): 157-162
1990
ISSN/ISBN: 0011-9083 PMID: 2365110 Document Number: 354874
8 patients with confirmed psoriatic arthritis were treated with splenopentin for 12 months. A relief of joint pain could be detected under this treatment both after 6 weeks (improvement of the Ritchie-indices: 44%) and after 12 months (improvement: 28%). In contrast to this, X-ray investigations show a worsening of the disease after 12 months. Therefore we conclude that splenopentin alone is not a sufficient therapeutic drug in patients suffering from psoriatic arthritis.